These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 23636669)

  • 1. Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.
    Pecci A
    Int J Hematol; 2013 Jul; 98(1):34-47. PubMed ID: 23636669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guest editorial: Pathophysiology and management of thrombocytopenia: possible clinical application of TPO receptor agonists.
    Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):8-9. PubMed ID: 23793996
    [No Abstract]   [Full Text] [Related]  

  • 3. The biology of thrombopoietin and thrombopoietin receptor agonists.
    Kuter DJ
    Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
    Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
    Elife; 2021 Jun; 10():. PubMed ID: 34059198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology and management of primary immune thrombocytopenia.
    Kashiwagi H; Tomiyama Y
    Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.
    Townsley DM; Desmond R; Dunbar CE; Young NS
    Int J Hematol; 2013 Jul; 98(1):48-55. PubMed ID: 23690288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.
    Bastida JM; Gonzalez-Porras JR; Rivera J; Lozano ML
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
    Machlus KR; Wu SK; Vijey P; Soussou TS; Liu ZJ; Shacham E; Unger TJ; Kashyap T; Klebanov B; Sola-Visner M; Crochiere M; Italiano JE; Landesman Y
    Blood; 2017 Aug; 130(9):1132-1143. PubMed ID: 28630120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists.
    Bussel J; Kulasekararaj A; Cooper N; Verma A; Steidl U; Semple JW; Will B
    Semin Hematol; 2019 Oct; 56(4):262-278. PubMed ID: 31836033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin in thrombocytopenias of childhood.
    Dame C
    Semin Thromb Hemost; 2001 Jun; 27(3):215-28. PubMed ID: 11446655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Milestones in understanding platelet production: a historical overview.
    Kuter DJ
    Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin receptor agonists in primary immune thrombocytopenia.
    Siegal D; Crowther M; Cuker A
    Semin Hematol; 2013 Jan; 50 Suppl 1(0 1):S18-21. PubMed ID: 23664510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
    Makar RS; Zhukov OS; Sahud MA; Kuter DJ
    Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
    Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
    Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.
    Fox NE; Lim J; Chen R; Geddis AE
    Exp Hematol; 2010 May; 38(5):384-91. PubMed ID: 20188141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietic agents.
    Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
    Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis.
    Fukushima-Shintani M; Suzuki K; Iwatsuki Y; Abe M; Sugasawa K; Hirayama F; Kawasaki T
    Exp Hematol; 2008 Oct; 36(10):1337-42. PubMed ID: 18619724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of mouse models to the understanding of constitutional thrombocytopenia.
    Léon C; Dupuis A; Gachet C; Lanza F
    Haematologica; 2016 Aug; 101(8):896-908. PubMed ID: 27478199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs.
    Qi X; De Stefano V; Guo X; Fan D
    Thromb Haemost; 2015 Jun; 113(6):1378-80. PubMed ID: 25761530
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.